WallStreetZenWallStreetZen

NASDAQ: BPMC
Blueprint Medicines Corp Stock

$94.79+5.12 (+5.71%)
Updated Mar 27, 2024
BPMC Price
$94.79
Fair Value Price
N/A
Market Cap
$5.80B
52 Week Low
$41.54
52 Week High
$101.00
P/E
-11.32x
P/B
44.44x
P/S
22.4x
PEG
N/A
Dividend Yield
N/A
Revenue
$249.38M
Earnings
-$506.98M
Gross Margin
94.9%
Operating Margin
-195.37%
Profit Margin
-203.3%
Debt to Equity
7.03
Operating Cash Flow
-$437M
Beta
1.15
Next Earnings
May 2, 2024
Ex-Dividend
N/A
Next Dividend
N/A

BPMC Overview

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BPMC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

BPMC is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BPMC is poor value based on its book value relative to its share price (44.44x), compared to the US Biotechnology industry average (6.2x)
P/B vs Industry Valuation
BPMC is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more BPMC due diligence checks available for Premium users.

Be the first to know about important BPMC news, forecast changes, insider trades & much more!

BPMC News

Valuation

BPMC fair value

Fair Value of BPMC stock based on Discounted Cash Flow (DCF)
Price
$94.79
Fair Value
$84.90
Overvalued by
11.65%
BPMC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

BPMC price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-11.32x
Industry
14.3x
Market
44.45x

BPMC price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
44.44x
Industry
6.2x
BPMC is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

BPMC's financial health

Profit margin

Revenue
$72.0M
Net Income
-$110.9M
Profit Margin
-154.1%
BPMC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BPMC's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$1.0B
Liabilities
$918.6M
Debt to equity
7.03
BPMC's short-term assets ($808.39M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BPMC's short-term assets ($808.39M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BPMC's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
BPMC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$78.9M
Investing
$78.8M
Financing
$15.5M
BPMC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

BPMC vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
BPMC$5.80B+5.71%-11.32x44.44x
CRSP$5.63B-1.14%-36.16x2.99x
BBIO$5.43B+3.70%-7.81x-4.01x
RVMD$5.22B+5.73%-8.22x2.86x
HALO$5.17B+1.62%19.12x61.64x

Blueprint Medicines Stock FAQ

What is Blueprint Medicines's quote symbol?

(NASDAQ: BPMC) Blueprint Medicines trades on the NASDAQ under the ticker symbol BPMC. Blueprint Medicines stock quotes can also be displayed as NASDAQ: BPMC.

If you're new to stock investing, here's how to buy Blueprint Medicines stock.

What is the 52 week high and low for Blueprint Medicines (NASDAQ: BPMC)?

(NASDAQ: BPMC) Blueprint Medicines's 52-week high was $101.00, and its 52-week low was $41.54. It is currently -6.15% from its 52-week high and 128.19% from its 52-week low.

How much is Blueprint Medicines stock worth today?

(NASDAQ: BPMC) Blueprint Medicines currently has 61,232,297 outstanding shares. With Blueprint Medicines stock trading at $94.79 per share, the total value of Blueprint Medicines stock (market capitalization) is $5.80B.

Blueprint Medicines stock was originally listed at a price of $18.87 in Apr 30, 2015. If you had invested in Blueprint Medicines stock at $18.87, your return over the last 8 years would have been 402.33%, for an annualized return of 22.36% (not including any dividends or dividend reinvestments).

How much is Blueprint Medicines's stock price per share?

(NASDAQ: BPMC) Blueprint Medicines stock price per share is $94.79 today (as of Mar 27, 2024).

What is Blueprint Medicines's Market Cap?

(NASDAQ: BPMC) Blueprint Medicines's market cap is $5.80B, as of Mar 28, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Blueprint Medicines's market cap is calculated by multiplying BPMC's current stock price of $94.79 by BPMC's total outstanding shares of 61,232,297.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.